SetPoint System
SetPoint Medical · Decision date Oct 29, 2026
What did the FDA decide?
The FDA record shows an approval decision (OK30) dated 2026-10-29 for SetPoint System supplement P240039/S004, filed as a 30-Day Notice with the reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The source statement describes reducing endotoxin monitoring from every lot to quarterly testing, with sampling of at least one lot manufactured each quarter. The record lists the device category as a vagus nerve stimulator for rheumatoid arthritis under product code SFJ.
The identifier establishes this as a supplement to PMA P240039, not a new approval of the whole system. The source statement's stated purpose is a manufacturing monitoring change; it does not present safety or clinical effectiveness data, so the decision record does not itself prove either. The fields supplied give no detail on which manufacturing site, test method, or acceptance criteria the quarterly sampling covers; those specifics are absent from the source.
FDA approval order statement
Approval for reducing endotoxin monitoring from every lot to quarterly, sampling at least one lot manufactured each quarter
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Oct 29, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240039/S004
- Regulatory pathway
- PMA supplement
- Applicant
- SetPoint Medical
- Product code
- SFJ
- Decision code
- OK30
- Decision date
- Oct 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Vagus nerve stimulator for rheumatoid arthritis.
- Applicant
- SetPoint Medical
- Product code
- SFJ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240039. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240039 · Original PMA
SetPoint System
P240039/S004 received
Application receipt date recorded by FDA.
P240039/S003 · Related supplement
Charger SetPoint System
P240039/S004 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P240039. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240039
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SetPoint SystemP240039 | SetPoint Medical | PMA approval | Jul 30, 2025 | FDA |
Charger SetPoint SystemP240039/S003 | SetPoint Medical | PMA supplement | Oct 16, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
SetPoint Medical
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 25101 Rye Canyon Loop, Valencia, CA, 91355
Sources and methodology
- Original FDA record: P240039/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
